Archive for July, 2009
Researchers at the National Institute of Environmental Health Sciences have long wanted to test some low-cost methods they thought could help prevent or treat chronic diseases, such as asthma, rheumatoid arthritis and cancer.
Within days of being published “Unscientific America” by Chris Mooney and Sheril Kirshenbaum triggered a heated debate about the compatibility of religion and science,, evidence-based research versus creationism and intelligent design, that has been going back and forth on the blogosphere.
Getting its first product, a painkiller, approved for sale was a triumph for BioDelivery Sciences.
Champagne corks popped at BDSI Thursday, the day the Food and Drug Administration let the small Raleigh drug development company know that Onsolis, a potent pain patch for cancer patients, had passed all regulatory hurdles. On Friday, analysts congratulated BDSI CEO Mark Sirgo during a conference call. By Monday, BDSI expected to have about $27 million more in the bank, a payment its Swedish partner Meda promised upon regulatory approval of Onsolis.
“It’s been a long haul,” Sirgo told analysts in the call Friday. “This is a fantastic day for our company.”
So why did BDSI’s stock drop 5 percent on a day when it should have risen?
When you get a bunch of people over 30 to talk about sex, there’s a good chance the conversation will involve babies. Sprinkle in a healthy dose of Generation Xers and baby boomers and fertility is sure to come up.
Cornerstone Therapeutics, a Cary company that specializes in respiratory therapies, has offered to pay $5 million for the commercial rights to Factive, a respiratory anitbiotic that generated $16 million in sales last year.
A few weeks after being challenged by former Gov. Jim Hunt to go and recruit Chinese companies to North Carolina, Keith Crisco, the state’s new commerce secretary, offered a response at a China business forum Tuesday at Brier Creek Country Club.
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.